Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$134.97 USD
+1.90 (1.43%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $135.07 +0.10 (0.07%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Brokerage Reports
0 items in cart
Neurocrine Biosciences, Inc. [NBIX]
Reports for Purchase
Showing records 201 - 220 ( 307 total )
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Momentum on Multiple Fronts; Reit Buy and Raising PT to $162
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Utilizing Growth of Ingrezza Revenue to Invest in Ingrezza
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
2018 Ought to Be a Catalyst-Filled Year; Reit Buy and $139PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Ingrezza Strength Reaffirms Our Bull Case; Reit Buy and Raising PT to $139
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Strong Ingrezza Launch Lifts the Tone for Quarters Ahead
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Strong Ingrezza Launch Lifts the Tone for Quarters Ahead
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Moderating Near-Term Forecasts Following Physician Feedback; Long-Term Bullishness Intact, Reit Buy and $130 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
With Ingrezza On Track for TD, Focus Shifts Back to Pediatric Data in Tourette?s; Raising PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Proprietary Survey of 100 Physicians Points to Ingrezza Bullishness: Reit Buy and $100 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Proprietary Physician Survey Frames Value of Opicapone Deal; Reit Buy and Raising PT to $100
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A